A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

  • Solid Tumors
Trial Status:


This trial runs in
  • Adana
  • Ankara
  • Asvestochori
  • Athens
  • bad-saarow
  • Bayrut
  • Bengaluru
  • Beograd
  • Besançon
  • Bogotá
  • Bratislavský kraj
  • Brest
  • Buenos Aires
  • Calgary
  • Cali
  • Cebu City
  • Chennai
  • Ciudad de México
  • Dublin 24
  • Dublin 8
  • Edirne
  • Golnik
  • Halle (Saale)
  • Hannover
  • Hanoi
  • Heilbronn
  • heroica-puebla-de-zaragoza
  • Hyderabad
  • İstanbul
  • Jerusalem
  • Johannesburg
  • Kaohsiung City
  • Krung Thep Maha Nakhon
  • Las Condes
  • Levallois-Perret
  • Lille
  • Medellín
  • Mumbai
  • Ottawa
  • Palma
  • Pamplona
  • Paris
  • Pireas
  • Porto
  • Pretoria
  • Quimper
  • Rennes
  • Rio Grande do Sul
  • Riyadh
  • Saint-Priest-en-Jarez
  • Saint-Étienne
  • Santiago
  • Sremska Kamenica
  • Stuttgart
  • São Paulo
  • Taipei City
  • Tallinn
  • Taoyuan City
  • Tartu
  • Tel Aviv-Yafo
  • Thessaloniki
  • Thành phố Hồ Chí Minh
  • Villejuif
  • Warszawa
  • Wesel
  • Zaragoza
  • دبي
Trial Identifier:

NCT04529122 MX39897

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

      Hoffmann-La Roche Sponsor
      NCT04529122 , MX39897 Trial Identifier
      Solid Tumours Condition
      Official Title

      A Registry to Collect the Natural History of Solid Tumour Cancers in Patients Profiled With a Next-Generation Sequencing Test (WAYFIND-R)

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participant is an adult (according to the age of majority as defined by local regulations)
      • Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
      • Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
      • Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
      Exclusion Criteria
      • Participant has a prior or current diagnosis of haematological malignancy

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now